HCSC coverage for Zepbound (Weight Loss)

Employer / Commercial Insurance

Covered with requirements

What you need to qualify

Age 12 and older
BMI of 30 or higher
BMI of 27 or higher with a weight-related condition (HTN, T2DM, OSA, CVD, and dyslipidemia)
BMI of 25 or higher for patients of Asian descent
BMI at or above the 95th percentile for age and sex
6 months of a documented diet and exercise program

Qualification pathways

You can qualify through any one of these.

Adult weight management

All of:

Patient is new to therapy, new to Prime, or attempting a repeat weight loss course
Patient is an adult (18 years of age or over)
Inadequate response to low-calorie diet, increased physical activity, and behavioral modifications for a minimum of 6 months prior to therapy
Patient is currently on and will continue weight management regimen in combination with the requested agent
Patient will NOT use requested agent in combination with another weight loss agent (e.g., Contrave, phentermine, Qsymia, Xenical)
Patient will NOT use requested agent in combination with another GLP-1 receptor agonist
Patient does NOT have any FDA labeled contraindications
ONE of the Zepbound continuation criteria met: starting therapy, less than 52 weeks of therapy, or achieved and maintained >= 5% weight loss from baseline

Plus any one of:

Pretreatment BMI >= 30 kg/m2
Pretreatment BMI >= 25 kg/m2 if patient is of South Asian, Southeast Asian, or East Asian descent
Pretreatment BMI >= 27 kg/m2 with at least one weight-related comorbidity/risk factor/complication (e.g., hypertension, T2DM, OSA, CVD, dyslipidemia)

Pediatric weight management (12-17 years)

All of:

Patient is new to therapy, new to Prime, or attempting a repeat weight loss course
Patient is pediatric (12 to 17 years of age)
Inadequate response to low-calorie diet, increased physical activity, and behavioral modifications for a minimum of 6 months prior to therapy
Patient is currently on and will continue weight management regimen in combination with the requested agent
Patient will NOT use requested agent in combination with another weight loss agent
Patient will NOT use requested agent in combination with another GLP-1 receptor agonist
Patient does NOT have any FDA labeled contraindications
ONE of the Zepbound continuation criteria met: starting therapy, less than 52 weeks of therapy, or achieved and maintained >= 5% weight loss from baseline

Plus any one of:

Pretreatment BMI >= 95th percentile for age and sex
Pretreatment BMI >= 30 kg/m2
Pretreatment BMI >= 85th percentile for age and sex AND at least one weight-related comorbidity/risk factor/complication (e.g., hypertension, dyslipidemia, T2DM, OSA)

Another FDA labeled indication (weight management pathway override)

All of:

Patient has another FDA labeled indication for the requested agent and route of administration
Patient will NOT use requested agent in combination with another weight loss agent
Patient will NOT use requested agent in combination with another GLP-1 receptor agonist
Patient does NOT have any FDA labeled contraindications
Patient is currently on and will continue weight management regimen

Documentation to bring

Baseline BMI documentation
Documentation of at least 6 months of inadequate response to low-calorie diet, increased physical activity, and behavioral modifications (for initial approval)
Documentation that patient is currently on weight management regimen (diet, physical activity, behavioral modifications)
For Asian descent patients: documentation of ethnicity supporting lower BMI threshold
For patients with comorbidities qualifying at BMI >= 27: documentation of qualifying comorbidity
For pediatric patients: documentation of BMI percentile for age and sex
Confirmation that patient will not combine with another weight loss agent or GLP-1 RA
For continuation: documentation of weight loss >= 5% from baseline OR documentation of being within 52 weeks of therapy on maximum-tolerated dose

Quantity limits

2.5 MG/0.5ML vial — 2 mL per 180-day supply (84-day)
5 MG/0.5ML vial — 2 mL per 28-day supply
7.5 MG/0.5ML vial, 10 MG/0.5ML vial, 12.5 MG/0.5ML vial, 15 MG/0.5ML vial — 4 vials per 28-day supply
2.5 MG/0.5ML autoinjector — 4 pens per 180-day supply (84-day)
5 MG/0.5ML autoinjector, 7.5 MG/0.5ML autoinjector, 10 MG/0.5ML autoinjector, 12.5 MG/0.5ML autoinjector, 15 MG/0.5ML autoinjector — 4 pens per 28-day supply
2.5 MG/0.6ML kwikpen — 1 pen per 180-day supply (84-day)
5 MG/0.6ML kwikpen, 7.5 MG/0.6ML kwikpen, 10 MG/0.6ML kwikpen, 12.5 MG/0.6ML kwikpen, 15 MG/0.6ML kwikpen — 1 pen per 28-day supply

Approval and renewal

Initial approval: 12 months
Renewal: every 12 months
To renew, the plan looks for at least 5% weight loss from the starting weight and For renewal (weight management): patient must have received less than 52 weeks of therapy on the maximum-tolerated dose OR achieved and maintained >= 5% weight loss from baseline. Pediatric patients must also maintain BMI >= 85th percentile at renewal. Initial BMI thresholds and 6-month lifestyle program pre-therapy requirement are not explicitly re-verified at renewal. Make sure your starting weight and date are in the chart now — renewal is measured against it.

Not covered when

Combination use with another weight loss agent (e.g., Contrave, phentermine, Qsymia, Xenical)
Combination use with another GLP-1 receptor agonist
Any FDA labeled contraindications to the requested agent

Exceptions

BCBS_NM_Fully_Insured_or_HIM: May be approved if patient does not have FDA labeled contraindications AND the requested indication is a rare disease AND patient has another FDA labeled indication or compendia-supported indication.
Ohio_Fully_Insured_or_HIM_SHOP: May be approved if member resides in Ohio, plan is Fully Insured or HIM Shop (SG), no FDA labeled contraindications, AND patient has another FDA labeled or compendia-supported indication OR prescriber submits two articles from major peer-reviewed journals.

Policy note: Approval duration for BCBS IL HIM/FI/ASO Cost (BBF) and BCBSMT FI & HIM is 12 months. For all other plans: initial and renewal approval is 12 months. Zepbound includes vial, autoinjector (soln autoinjector), and kwikpen (soln pen-injector) formulations. Note Zepbound is also covered under a separate OSA indication with different criteria.

Policy effective May 18, 2026 · verified June 2, 2026 · source: HCSC_Weight_Management_ProgSum.pdf